Edwards Lifesciences Corp. (EW: Quote) announced after the bell Wednesday that an FDA Advisory Panel voted in favor of recommending approval of the Edwards SAPIEN transcatheter heart valve via transfemoral and transapical delivery, for the treatment of high-risk patients with severe, symptomatic aortic stenosis.
Edwards Lifesciences has spiked to the upside in early trade and is now up 4.15 at $94.69. The stock has been climbing for the last week and a half and has surged to a new high for the year.
Click here to receive FREE breaking news email alerts for Edwards Lifesciences Corp. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com